Previous 10 | Next 10 |
2023-05-02 16:10:04 ET Sarepta Therapeutics press release ( NASDAQ: SRPT ): Q1 GAAP EPS of -$5.86 misses by $4.57 . Revenue of $253.5M (+20.3% Y/Y) beats by $12.03M . For further details see: Sarepta Therapeutics GAAP EPS of -$5.86 misses by $4.57, revenu...
Total revenues, which consist of net product revenues and collaboration revenues, for the first quarter 2023 totaled $253.5 million Net product revenues for the first quarter 2023 totaled $231.5 million, a 23% increase over the same quarter of prior year Sarepta Therapeu...
2023-05-02 08:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-04-29 16:00:00 ET With the first trading day in May coming on Monday, many pharmaceutical companies will be hoping their returns fare better than they did in April. The iShares U.S. Pharmaceuticals ETF ( IHE ) returned a paltry 1.6% in April. The ETF's top two holdings are ...
2023-04-29 04:20:36 ET Summary Demographic trends are powerful and experience little impact from economic cycles. As the Millennial generation enters middle age and surpasses the number of Baby Boomers, the demand for medical screening and testing will increase. Exact Sciences...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2023 financial results after the Nasdaq Global Market closes on Tuesday, May 2, 2023. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss...
2023-04-24 10:26:48 ET RNA therapeutics company Avidity Biosciences ( NASDAQ: RNA ) announced Monday that the FDA issued Fast Track designation for AOC 1044, its candidate for genetically driven muscular disorder Duchenne muscular dystrophy (DMD). The agency has issued the desig...
2023-04-22 16:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-04-19 09:15:05 ET Summary Sarepta Therapeutics develops RNA-targeted therapeutics and gene therapies for rare diseases, with approved products for Duchenne muscular dystrophy (DMD). The FDA will review the marketing application for Sarepta's DMD gene therapy, SRP-9001, after ...
ATLANTA, April 14, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Sarepta Therapeutics, Inc. (“Sarepta Therapeutics” or the “Company”) (NASDAQ: SRPT) complied with federal securities laws. On March 16, 2023, Sarepta Therapeutics annou...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...
2024-07-08 12:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...